Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524—A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation-Reference-Cited by-同舟云学术

Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524—A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation

Published:2024-02 Issue:1 Volume:7 Page:83-90
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Dahl Douglas M.^ORCID,Karrison Theodore G.,Michaelson M. Dror,Pham Huong T.,Wu Chin-Lee,Swanson Gregory P.,Shipley William U.,Vuky Jacqueline,Lee R. Jeffrey,Zietman Anthony L.,Souhami Luis,Chang Brian K.,Deming Richard L.,Ellerton John A.,Sandler Howard M.,Rodgers Joseph P.,Feng Felix Y.,Efstathiou Jason A.

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference17 articles.

1. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience;Efstathiou;Eur Urol,2012

2. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience;Giacalone;Eur Urol,2017

3. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline;Chang;J Urol,2017

4. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base;Gray;Eur Urol,2013

5. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group